If You Had Bought Fusen Pharmaceutical (HKG:1652) Stock A Year Ago, You Could Pocket A 96% Gain TodayHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)If You Had Bought Fusen Pharmaceutical (HKG:1652) Stock A Year Ago, You Could Pocket A 96% Gain TodaySimply Wall StSimply Wall St.January 8, 2020ReblogShareTweetShareView photosFusen Pharmaceutical Company Limited (HKG:1652) shareholders might be concerned after seeing the share price drop 17% in the last quarter. But that doesn't change the fact that the returns over the last year have been pleasing. Looking at the full year, the company has easily bested an index fund by gaining 96%. See our latest analysis for Fusen Pharmaceutical While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).During the last year, Fusen Pharmaceutical actually saw its earnings per share drop 45%.Given the share price gain, we doubt the market is measuring progress with EPS. Therefore, it seems likely that investors are putting more weight on metrics other than EPS, at the moment.We are skeptical of the suggestion that the 0.3% dividend yield would entice buyers to the stock. Unfortunately Fusen Pharmaceutical's fell 22% over twelve months. So using a snapshot of key business metrics doesn't give us a good picture of why the market is bidding up the stock.The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).SEHK:1652 Income Statement, January 8th 2020MoreTake a more thorough look at Fusen Pharmaceutical's financial health with this free report on its balance sheet.A Different PerspectiveFusen Pharmaceutical boasts a total shareholder return of 97% for the last year (that includes the dividends) . Unfortunately the share price is down 17% over the last quarter. It may simply be that the share price got ahead of itself, although there may have been fundamental developments that are weighing on it. Before forming an opinion on Fusen Pharmaceutical you might want to consider these 3 valuation metrics.But note: Fusen Pharmaceutical may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextWhy BE Group AB (publ) (STO:BEGR) Is A Dividend RockstarSimply Wall St.Should You Buy Antevenio, S.A. (EPA:ALANT) For Its Dividend?Simply Wall St.Here's What Absolent Group AB (publ)'s (STO:ABSO) P/E Is Telling UsSimply Wall St.Fu Yu Corporation Limited Just Released Its Annual Earnings: Here's What Analysts ThinkSimply Wall St.Citigroup, Goldman, JPMorgan Slash Earnings Estimates for StocksBloombergBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoAsian markets continue to slump, as Nikkei enters correction territoryMarketWatch'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video